- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06172946
Effect of Powerbreath Versus Transcutaneous Electrical Diaphragmatic Stimulation on The Severity of Copd
Effect of Inspiratory Muscle Training Versus Transcutaneous Electrical Diaphragmatic Stimulation on The Severity of Copd
Chronic obstructive pulmonary disease (COPD) is a common and treatable disease characterized by progressive airflow limitation and tissue destruction. It is associated with structural lung changes due to chronic inflammation from prolonged exposure to noxious particles or gases most commonly cigarette smoke.
POWERbreathe device (POWER-breathe International Ltd., Southam, Warwickshire, UK) is an inspiratory muscle training and this device has recently shown benefits on pulmonary function. Also, the POWER-breathe® device's effects on the strength of the diaphragm muscle and minimize muscle weakness and wasting in COPD patients.
Neuromuscular electrical stimulation (NMES) is commonly used in physical therapy to increase muscle strength and promote muscle hypertrophy. NMES applied to respiratory rehabilitation is called transcutaneous electrical diaphragmatic stimulation (TEDS).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
sixty Patients will be assigned randomly into two equal groups with pre and post treatment protocol application.
Group A:
Thirty patients will be treated by power breathe along with their prescribed medication.
Group B:
Thirty patients will be treated by Transcutaneous electrical Diaphragmatic Stimulation (TEDS) along with their prescribed medication.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alaa El-Moatasem, Lecturer
- Phone Number: 01006625054
- Email: alaamotasem@cu.edu.eg
Study Locations
-
-
-
Cairo, Egypt, 11432
- Recruiting
- Cairo University
-
Contact:
- Alaa El-Moatasem, Lecturer
- Phone Number: 01006625054
- Email: alaamotasem@cu.edu.eg
-
Principal Investigator:
- Alaa El-Moatasem, lecturer
-
Principal Investigator:
- Eman Abdel salam
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
The patient selection will be according to the following criteria:
- Male patients diagnosed with stage 3&4 COPD.
- All patients are under full medical control.
- Their ages will range from forty-five to sixty-five years.
- Patients with BMI from 25-29.9 kg/m2
Exclusion Criteria:
Patients with the following criteria will be excluded from the study:
- Lack of language or cognitive abilities to fill out questionnaire.
- Patients with cardiac pacemaker.
- Contraindications for inspiratory muscle training (e.g. a history of recent lung surgery, recent pulmonary embolism, history of recurrent spontaneous pneumothorax, other serious lung disease).
- Existing arterial aneurysm.
- Clinical signs of unstable cardiac event (eg. congestive heart failure).
- Patients with malignant disease.
- Acute COPD exacerbation within the last 4 weeks.
- Any need for supplemental oxygen.
- Patients with Gastro-esophageal reflux disease.
- Patients with active Hemoptysis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: INSPIRATORY MUSCLE TRAINING
Power Breathe: (3times/week for 8 weeks) The patient should inhale and exhale through the mouthpiece 30 times maximum. The training load is adjustable and should be set at a level appropriate for the patient to effectively train the inspiratory muscles. (Lázaro et al., 2021) |
Previous studies have confirmed the efficacy of implementing IMT as part of a RR program in a certain profile of patients with COPD, showing improvements in maximum inspiratory pressure, perception of well-being, and other respiratory diseases, and dyspnea during exercise.
(Gandullo et al., 2022)
|
Active Comparator: TRANSCUTANEOUS ELECTRICAL DIAPHRAGMATIC STIMULATION
Transcutaneous electrical Diaphragmatic Stimulation(TEDS): (3times/week for 8 weeks) During each session, rectangular electrodes were placed on the parasternal region beside the xiphoid process; the sixth and seventh intercostal spaces in line with the mid-axillary line. The electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. TEDS intensity was gradually increased until visible muscle contraction was observed. (Hsin et al., 2022) |
Transcutaneous electrical diaphragmatic stimulation (TEDS) has been used to improve respiratory muscle strength in patients with respiratory muscle weakness.
A previous study reported that patients with chronic obstructive pulmonary disease (COPD) showed increased lung volume and oxygen saturation after a single session of TEDS.
(Hsin et al., 2022)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The COPD Assessment Test (CAT)
Time Frame: COPD Assessment Test will be measured at baseline, and it will be measured again after eight weeks
|
The COPD Assessment Test(CAT) is validated questionnaire consisting of eight items, which evaluate the most burdensome symptoms and limitations of the patients.
The score for each item ranges from 0 to 5 and the total score (0-40)
|
COPD Assessment Test will be measured at baseline, and it will be measured again after eight weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary function: By Spirometry Device:
Time Frame: Pulmonary function: By Spirometry Device: forced vital capacity will be measured at baseline, and it will be measured again after eight weeks
|
• Pulmonary function: By Spirometry Device: it measure ventilatory functions.
forced vital capacity (FVC)
|
Pulmonary function: By Spirometry Device: forced vital capacity will be measured at baseline, and it will be measured again after eight weeks
|
Pulmonary function: By Spirometry Device:
Time Frame: Pulmonary function: By Spirometry Device: forced expiratory volume in one second will be measured at baseline, and it will be measured again after eight weeks
|
• Pulmonary function: By Spirometry Device: it measure ventilatory functions.
forced expiratory volume in one second (FEV1)
|
Pulmonary function: By Spirometry Device: forced expiratory volume in one second will be measured at baseline, and it will be measured again after eight weeks
|
Pulmonary function: By Spirometry Device:
Time Frame: Pulmonary function: By Spirometry Device: forced expiratory volume in one second/forced expiratory volume will be measured at baseline, and it will be measured again after eight weeks
|
• Pulmonary function: By Spirometry Device: it measure ventilatory functions.
forced expiratory volume in one second/forced expiratory volume (FEV1/FVC)
|
Pulmonary function: By Spirometry Device: forced expiratory volume in one second/forced expiratory volume will be measured at baseline, and it will be measured again after eight weeks
|
Pulmonary function: By Spirometry Device:
Time Frame: Pulmonary function: By Spirometry Device: forced expiratory flow will be measured at baseline, and it will be measured again after eight weeks
|
• Pulmonary function: By Spirometry Device: it measure ventilatory functions.
forced expiratory floe(FEF25-75%)
|
Pulmonary function: By Spirometry Device: forced expiratory flow will be measured at baseline, and it will be measured again after eight weeks
|
Diaphragmatic Thickness: By Ultrasonography:
Time Frame: Diaphragmatic Thickness: By Ultrasonography:will be measured at baseline, and it will be measured again after eight weeks
|
• Diaphragmatic Thickness: By Ultrasonography: provides a simple and non-invasive means of assessing diaphragmatic function.
(Boussuges et al., 2020)
|
Diaphragmatic Thickness: By Ultrasonography:will be measured at baseline, and it will be measured again after eight weeks
|
Measuring functional capacity: By Six-minute walk test (6MWT):
Time Frame: Measuring functional capacity: By Six-minute walk test (6MWT)::will be measured at baseline, and it will be measured again after eight weeks
|
• Measuring functional capacity: By Six-minute walk test (6MWT): is a self paced submaximal field exercise test , It will be performed according to the standard procedure is administered in a 30 meter hallway.
(Launois et al., 2012 and ATS statement2002)
|
Measuring functional capacity: By Six-minute walk test (6MWT)::will be measured at baseline, and it will be measured again after eight weeks
|
Modified Medical Research Council dyspnea scale (mMRC dyspnea scale):
Time Frame: Modified Medical Research Council dyspnea scale (mMRC dyspnea scale):will be measured at baseline, and it will be measured again after eight weeks
|
• Dyspnea: By Modified Medical Research Council dyspnea scale (mMRC dyspnea scale): It is a 5 point scale based on degrees of variable physical activities that precipitate dyspnea with a score ranging from 0 to 4. (Richards, 2017)
|
Modified Medical Research Council dyspnea scale (mMRC dyspnea scale):will be measured at baseline, and it will be measured again after eight weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P.T.REC/012/004626
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on powerbreath
-
Instituto de Cardiologia do Rio Grande do SulNot yet recruitingVascular Stiffness | Autonomic Imbalance | Postmenopausal DisorderBrazil
-
Universidade Federal de PernambucoRecruiting
-
Aveiro UniversityCompletedRespiratory FunctionPortugal
-
Universidad Francisco de VitoriaCompleted
-
Universidad Francisco de VitoriaCompletedAmyotrophic Lateral SclerosisSpain
-
Universidade Cidade de Sao PauloRecruitingMuscle Weakness | Bariatric Surgery Candidate | Complication,Postoperative | Respiratory MuscleBrazil
-
Universidade Federal de PernambucoCompletedSleep Apnea, ObstructiveBrazil